Igi

Igi company information, Employees & Contact Information

Explore related pages

Related company profiles:

IGI, Inc. is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics™ aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors.

Company Details

Employees
183
Founded
-
Address
1 World Trade Center, 76th Floor,suite D,switzerland
Industry
Biotechnology
HQ
New York, NY
Looking for a particular Igi employee's phone or email?

Igi Questions

News

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - GlobeNewswire

Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting GlobeNewswire

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate - Yahoo Finance

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreate Yahoo Finance

TRIgnite-1 study at ASCO 2025 showed High Response Rates and Favorable Safety Profile for the Treatment of Relapsed/Refractory Multiple Myeloma with First-in-Class BCMA × CD38 × CD3 Trispecific Antibody - Oncodaily

TRIgnite-1 study at ASCO 2025 showed High Response Rates and Favorable Safety Profile for the Treatment of Relapsed/Refractory Multiple Myeloma with First-in-Class BCMA × CD38 × CD3 Trispecific Antibody Oncodaily

Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology Asset ISB 2001 at AACR 2024 Annual Meeting - PR Newswire

Ichnos Glenmark Innovation Presents Preclinical Data for its Oncology Asset ISB 2001 at AACR 2024 Annual Meeting PR Newswire

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody - PR Newswire UK

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody PR Newswire UK

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24 - PR Newswire

Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24 PR Newswire

Top Igi Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant